Key statistics dashboard for Kiora Pharmaceuticals, Inc. (KPRX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials.
Stock Data
| Price | $2.60 |
| Market Cap | $12M |
| Beta | -0.77 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.04 |
| Price / Book | 0.95 |
| P/S | 0.00 |
| P/FCF | -1.34 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 8.97 |
| Quick Ratio | 8.97 |
| Cash Ratio | 2.99 |
| Debt / Equity | 0.02 |
| Debt / Assets | 1.40% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 2.73 |
| Cash per share | 2.73 |
| FCF per share | -1.39 |
| Tangible Book Value per share | 2.39 |
| Dividend per share | 0.00 |
Related companies: ACXP · ADIL · APRE · APVO · BCDA · CELZ · HCWB
Explore sector: Healthcare · Biotechnology
More sections of KPRX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks